000724255 000__ 03712cam\a2200493Ii\4500
000724255 001__ 724255
000724255 005__ 20230306140523.0
000724255 006__ m\\\\\o\\d\\\\\\\\
000724255 007__ cr\cn\nnnunnun
000724255 008__ 141112s2015\\\\sz\\\\\\ob\\\\000\0\eng\d
000724255 019__ $$a899584263$$a908083467
000724255 020__ $$a9783319105277$$qelectronic book
000724255 020__ $$a3319105272$$qelectronic book
000724255 020__ $$z9783319105260
000724255 020__ $$z3319105264
000724255 0247_ $$a10.1007/978-3-319-10527-7$$2doi
000724255 035__ $$aSP(OCoLC)ocn895047509
000724255 035__ $$aSP(OCoLC)895047509$$z(OCoLC)899584263$$z(OCoLC)908083467
000724255 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dYDXCP$$dCOO$$dIDEBK$$dEBLCP
000724255 049__ $$aISEA
000724255 050_4 $$aRC159.A5
000724255 08204 $$a616.9362061$$223
000724255 1001_ $$aKiang, Tony K. L.,$$eauthor.
000724255 24510 $$aClinical pharmacokinetic and pharmacodynamic drug interactions associated with antimalarials$$h[electronic resource] /$$cTony K.L. Kiang, Kyle John Wilby, Mary H.H. Ensom.
000724255 264_1 $$a[Cham] :$$bAdis,$$c[2015]
000724255 264_4 $$c©2015
000724255 300__ $$a1 online resource.
000724255 336__ $$atext$$btxt$$2rdacontent
000724255 337__ $$acomputer$$bc$$2rdamedia
000724255 338__ $$aonline resource$$bcr$$2rdacarrier
000724255 504__ $$aIncludes bibliographical references.
000724255 5050_ $$aIntroduction -- Pharmacology of Recommended Antimalarial Agents -- Drug Interaction Potential of Antimalarial Drugs Based on Known Metabolic Properties of Antimalarials -- Pharmacokinetic Drug Interactions Affecting Antimalarials -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Drugs -- Effects of Antimalarials on the Pharmacokinetics of Co-Administered Antimalarials -- Pharmacodynamic Interactions: Clinical Evidence for Combination Therapy, In Vitro Interactions, and In Vivo Interactions -- Limitations, Future Directions, and Conclusions.
000724255 506__ $$aAccess limited to authorized users.
000724255 520__ $$aThis comprehensive review provides a systematic, unbiased analysis, critique and summary of the available literature and generates novel clinical decision-making algorithms which can aid clinicians and scientists in practice management and research development. Potential mechanisms for the identified drug interactions are deduced from available preclinical and in vitro data which are interpreted in the context of the in vivo findings. Current limitations and gaps in the literature are summarized, and potential future research directions / experimentations are also suggested. In addition to the main objective to review the available clinical pharmacokinetic and pharmacodynamic drug interactions associated with WHO-recommended antimalarial drugs on the market today (i.e. chloroquine, amodiaquine, sulfadoxine, pyrimethamine, mefloquine, artemisinin, artemether, artesunate, dihydroartemisinin, artemotil, lumefantrine, primaquine, atovaquone, proguanil, piperaquine and quinine), this book also provides succinct chapter summaries on the epidemiology of malaria infection, diagnosis and therapeutics, in vivo pharmacology and chemistry, preclinical pharmacology, in vitro pharmacodynamics, in vitro reaction phenotyping, and in vitro drug-drug interaction data associated with the identified antimalarial drugs.
000724255 588__ $$aOnline resource; title from pdf information screen (viewed November 14, 2014).
000724255 650_0 $$aAntimalarials$$xPharmacokinetics.
000724255 650_0 $$aAntimalarials$$xReceptors$$xEffect of drugs on.
000724255 7001_ $$aWilby, Kyle John,$$eauthor.
000724255 7001_ $$aEnsom, Mary H.H.,$$eauthor.
000724255 77608 $$iPrint version:$$z3319105264$$z9783319105260
000724255 852__ $$bebk
000724255 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-10527-7$$zOnline Access$$91397441.1
000724255 909CO $$ooai:library.usi.edu:724255$$pGLOBAL_SET
000724255 980__ $$aEBOOK
000724255 980__ $$aBIB
000724255 982__ $$aEbook
000724255 983__ $$aOnline
000724255 994__ $$a92$$bISE